Cencora, Inc. (COR)
(Delayed Data from NYSE)
$225.30 USD
-2.66 (-1.17%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $225.11 -0.19 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.30 USD
-2.66 (-1.17%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $225.11 -0.19 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain BD (BDX) to Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
by Zacks Equity Research
One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.
GE HealthCare (GEHC) AI Model to Predict Immunotherapy Response
by Zacks Equity Research
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.
Cardinal Health (CAH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius Medical (FMS) Divests Assets to Optimize Portfolio
by Zacks Equity Research
Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend
by Zacks Equity Research
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
Labcorp (LH) Introduces Weight Loss Management Portfolio
by Zacks Equity Research
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
by Zacks Equity Research
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System
by Zacks Equity Research
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
by Zacks Equity Research
Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.
DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?
by Zacks Equity Research
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
by Zacks Equity Research
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
QuidelOrtho's (QDEL) New Approval to Aid Pre-eclampsia Diagnosis
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
by Zacks Equity Research
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
Should JPMorgan Diversified Return U.S. Equity ETF (JPUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPUS
Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable
by Zacks Equity Research
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
DaVita (DVA) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DaVita's (DVA) strength in its kidney care.